Ueda, Ryo

写真a

Affiliation

School of Medicine, Department of Neurosurgery (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

External Links

 

Papers 【 Display / hide

  • [Endoscopic Endonasal Skull Base Surgery Using the 'Four Hands-Two Nostrils' Technique by a Surgical Team Composed of an ENT Surgeon and a Neurosurgeon].

    Toda M, Ueda R, Ozawa H

    No shinkei geka. Neurological surgery 48 ( 10 ) 885 - 893 2020.10

    ISSN  0301-2603

  • Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - A case series

    Tamura R., Morimoto Y., Kosugi K., Sato M., Oishi Y., Ueda R., Kikuchi R., Nagashima H., Noji S., Kawakami Y., Sasaki H., Yoshida K., Toda M.

    BMC Cancer (BMC Cancer)  20 ( 1 )  2020.03

     View Summary

    © 2020 The Author(s). Background: The expression of vascular endothelial growth factor (VEGF)-A/ VAGF receptors (VEGFRs) signaling plays a pivotal role in the tumor angiogenesis and the development of the immunosuppressive tumor microenvironment in glioblastomas. We have previously conducted exploratory clinical studies investigating VEGFRs peptide vaccination with and without multiple glioma oncoantigens in patients with recurrent high-grade gliomas. Recently, an exploratory clinical investigation of VEGFRs peptide vaccination was conducted in patients with progressive neurofibromatosis type 2. Those studies suggested that cytotoxic T lymphocytes (CTLs) induced by the vaccination can directly kill a wide variety of cells associated with tumor growth, including tumor vessels, tumor cells, and immunosuppressive cells expressing VEGFR1 and/or 2. In the present study, synergistic activity of the combination of VEGFRs peptide vaccination with chemotherapy was evaluated. Methods: We performed the first clinical trial to assess VEGFR1 and 2 vaccination along with temozolomide (TMZ) -based chemoradiotherapy for the patients with primary glioblastomas. Furthermore, histopathological changes after the vaccination were evaluated using paired pre- and post- vaccination specimens. Results: The disappearance of radiographically enhanced lesion was observed in 2 patients after the vaccination, including one in which the methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter was not observed. The histopathological findings of pre- and post-vaccination specimens demonstrated that tumor vessels showed negative or slight VEGFRs expressions after the vaccination and most endothelial cells were covered with PDGFR-β-positive pericytes. Notably, CTLs induced by VEGFRs peptide vaccination attacked not only tumor vessels but also tumor cells and regulatory T cells expressing VEGFRs even in recurrent tumors. Conclusions: VEGFR1 and 2 vaccination may have a preliminary synergistic effect when administered with TMZ. The limitation of the present study was the paucity of the number of the samples. Further studies involving more patients are warranted to confirm the findings of this study. Trial registration: This study was registered as UMIN000013381 (University Hospital Medical Information Network-Clinical Trial Registry: UMIN-CTR) on 5 March, 2014 and with the Japan Registry of Clinical Trials (jRCT) as jRCTs031180170 on 1 March, 2019.

  • Efficacy of a topical gelatin-thrombin hemostatic matrix, FLOSEAL®, in intracranial tumor resection

    Kamamoto D., Kanazawa T., Ishihara E., Yanagisawa K., Tomita H., Ueda R., Jinzaki M., Yoshida K., Toda M.

    Surgical Neurology International (Surgical Neurology International)  11 ( 16 )  2020.02

     View Summary

    © 2020 Scientific Scholar. All rights reserved. Background: Hemostasis plays an important role in safe brain tumor resection and also reduces the risk for surgical complications. This study aimed to evaluate the efficacy of FLOSEAL®, a topical hemostatic agent that contains thrombin and gelatin granules, in brain tumor resections. Methods: We evaluated the hemostatic effect of FLOSEAL by scoring the intensity of bleeding from 1 (mild) to 4 (life threatening). We assessed the rate of success of hemostasis with 100 patients who underwent intracranial tumor resection. We also investigated the duration of the operation, the amount of intra- and postoperative bleeding, the number of hospital stays, and adverse events in patients who used FLOSEAL compared with those who did not use FLOSEAL. Results: FLOSEAL was applied to a total of 109 bleeding areas in 100 patients. A total of 95 bleeding areas had a score of 1 and 91 (96%) showed successful hemostasis. Thirteen bleeding areas scored 2 and 8 (62%) showed hemostasis with the first application of FLOSEAL. The second application was attempted with five bleeding areas and four showed hemostasis. About 94% (103/109 areas) of bleeding points successfully achieved hemostasis by FLOSEAL. Moreover, FLOSEAL significantly decreased the amount of intraoperative bleeding and postoperative bleeding as assessed with computed tomography on 1 day postoperatively compared with no use of FLOSEAL. There were no adverse events related to FLOSEAL use. Conclusion: Our results indicate that FLOSEAL is a reliable, convenient, and safe topical hemostatic agent for intracranial tumor resection.

  • Otitis media cholesteatoma was suggested as a cause of brain venous sinus thrombosis because of the presence of otorrhea: a case report

    Fuse Akihisa, Kitazono Hisao, Nagata Naomi, Uchi Takafumi, Ueda Ryo, Nozaki Hiroyuki

    Japanese Journal of Stroke (The Japan Stroke Society)   2020

    ISSN  0912-0726

     View Summary

    <p>Case: A 17-year-old man was brought to our hospital by ambulance due to a severe headache and vomit. The meningeal irritation and right abducens nerve paralysis were found on neurologic examination. Head computed tomography (CT) revealed poor growth of the right mastoid pneumatization and a high absorption area in the sinus sagittalis superior from the right lateral venous sinus. On cerebral angiography, there was no depiction of the right sigmoid sinus, and thrombus was observed in sinus sagittalis superior. Therefore, it was diagnosed as cerebral venous sinus thrombosis. The cause of thrombosis was unknown a blood test. After admission the patient had right otorrhea. After examination, right otitis media cholesteatoma was found. Treatment was commenced with hypothesis thatotitis media cholesteatoma was involved as a cause of cerebral venous sinus thrombosis. Later, the symptoms resolved, and the patient was discharged. In cerebral venous sinus thrombosis, we should consider the possibility of otitis media cholesteatoma as a cause due to poor growth of the mastoid pneumatization as seen on head CT.</p>

  • A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

    Tamura R., Fujioka M., Morimoto Y., Ohara K., Kosugi K., Oishi Y., Sato M., Ueda R., Fujiwara H., Noji S., Oishi N., Ogawa K., Kawakami Y., Ohira T., Yoshida K., Toda M.

    Nature Communications (Nature Communications)  10 ( 1 )  2019.12

     View Summary

    © 2019, The Author(s). The anti-VEGF antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Theoretically, vascular endothelial growth factor receptors (VEGFRs)-specific cytotoxic T lymphocytes (CTLs) can kill both tumor vessel cells and tumor cells expressing VEGFRs. Here we show an exploratory clinical study of VEGFRs peptide vaccine in seven patients with progressive NF2-derived schwannomas. Hearing improves in 2/5 assessable patients (40%) as determined by international guidelines, with increases in word recognition scores. Tumor volume reductions of ≥20% are observed in two patients, including one in which bevacizumab had not been effective. There are no severe adverse events related to the vaccine. Both VEGFR1-specific and VEGFR2-specific CTLs are induced in six patients. Surgery is performed after vaccination in two patients, and significant reductions in the expression of VEGFRs in schwannomas are observed. Therefore, this clinical immunotherapy study demonstrates the safety and preliminary efficacy of VEGFRs peptide vaccination in patients with NF2.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

    Tamura R., Fujioka M., Morimoto Y., Ohara K., Kosugi K., Oishi Y., Sato M., Ueda R., Fujiwara H., Hikichi T., Noji S., Oishi N., Ogawa K., Kawakami Y., Ohira T., Yoshida K., Toda M.

    Nature Communications (Nature Communications)  11 ( 1 )  2020.12

     View Summary

    © 2020, The Author(s). The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

  • 解剖を中心とした脳神経手術手技 脳神経外科と耳鼻科合同による経鼻内視鏡頭蓋底手術

    戸田 正博, 植田 良, 小澤 宏之

    Neurological Surgery ((株)医学書院)  48 ( 10 ) 885 - 893 2020.10

    ISSN  0301-2603

     View Summary

    <文献概要>I.はじめに 近年の内視鏡手術の発展に伴い,脳神経外科においても経鼻内視鏡手術が普及しつつある.さらに,さまざまな副鼻腔空間を経由して頭蓋底に到達する経鼻内視鏡頭蓋底手術(endoscopic endonasal skull base surgery:EESS)は,手術手技の効率化やエビデンスの蓄積とともに,頭蓋底疾患に対する治療選択肢として確立されつつある.EESSでは,脳神経外科医に馴染みのない領域の解剖知識や内視鏡手術特有の手技の習得が必要となる.本稿では,EESSを理解するための解剖・手術アプローチを中心に具体例を提示しつつ,さらにEESSに習熟した耳鼻科医とのチーム手術の実際と利点を交えながら概説する.

  • Erratum: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma-a case series (BMC Cancer (2020) 20 (196) DOI: 10.1186/s12885-020-6589-x)

    Tamura R., Morimoto Y., Kosugi K., Sato M., Oishi Y., Ueda R., Kikuchi R., Nagashima H., Hikichi T., Noji S., Kawakami Y., Sasaki H., Yoshida K., Toda M.

    BMC Cancer (BMC Cancer)  20 ( 1 )  2020.04

     View Summary

    © 2020 The Author(s). Following publication of the original article [1], the authors reported an error in the author group. It was reported that Tetsuro Hikichi was missing and the corrected author group is as follows: Ryota Tamura1, Yukina Morimoto1, Kenzo Kosugi1, Mizuto Sato1, Yumiko Oishi1, Ryo Ueda1, Ryogo Kikuchi2, Hideaki Nagashima1, Tetsuro Hikichi4, Shinobu Noji3, Yutaka Kawakami3, Hikaru Sasaki1, Kazunari Yoshida1 and Masahiro Toda1*The competing interests statement has been updated to: TH is an employee of OncoTherapy Science, Inc. The original article [1] has been corrected.

  • 当院で施行した内視鏡下頭蓋底手術について

    佐藤 陽一郎, 戸田 正博, 片山 真, 植田 良, 中原 奈々, 戸塚 大輔, 島貫 茉莉江, 蔵成 勇紀, 相馬 啓子

    神奈川医学会雑誌 (神奈川県医師会)  43 ( 2 ) 307 - 307 2016.07

    ISSN  0285-0680

  • 内視鏡頭蓋底手術における鼻中隔粘膜弁作成の工夫

    佐藤 陽一郎, 冨田 俊樹, 戸田 正博, 植田 良, 三浦 康士郎, 猪野 絢子, 岩井 貴洋, 冨岡 拓矢, 相馬 啓子

    日本耳鼻咽喉科学会会報 ((一社)日本耳鼻咽喉科学会)  118 ( 4 ) 539 - 539 2015.04

    ISSN  0030-6622

display all >>

Presentations 【 Display / hide

  • グリオーマ患者血清IgG抗体に認識される精巣組織由来グリオーマ抗原の単離と解析

    植田良,戸田正博,吉田一成,河上裕,河瀬斌

    第61回日本脳神経外科学会総会, 2002.10, Oral Presentation(general)

  • Serological identification of SOX D group proteins as highly immunogenic cancer-testis antigen in glioma

    Ueda Ryo, Toda Masahiro, Kawase Takeshi, Kawakami Yutaka

    American Association for Cancer Research. Annual Meeting, 2002.07, Oral Presentation(general)

  • 精巣組織由来のグリオーマ抗原遺伝子の単離

    植田良,戸田正博,吉田一成,河上裕,河瀬斌

    第6回Waterfront Neurosurgical Conference, 2002.07, Oral Presentation(general)

  • 精巣組織由来の新規グリオーマ抗原の単離

    植田良,戸田正博,吉田一成,河上裕,河瀬斌

    第23回ニューロオンコロジーの会, 2002.07, Oral Presentation(general)

  • Serological identification of SOX6 as highly immunogenic cancer-testis antigen in glioma

    植田良,戸田正博,吉田一成,河瀬斌,河上裕

    第8回基盤的癌免疫研究会, 2002.07, Oral Presentation(general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 悪性脳腫瘍新生血管を治療標的としたペプチドワクチン療法の有効性予測因子の解明

    2018.04
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 植田 良, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • Biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines against malignant glioma patients

    2015.04
    -
    2018.03

    Keio University, UEDA RYO, TODA MASAHIRO, Grant-in-Aid for Scientific Research (C)

     View Summary

    Evaluation of immunological biomarkers may lead to better understanding of the critical immune response indicators that may help to predict clinical responses of cancer immunotherapy. We characterized status of immune cells, cytokines, chemokines, and other immunosuppressive molecules in malignant glioma patients who received vaccinations of VEGF receptor (VEGFR)-derived peptides. Peripheral blood samples from patients who demonstrated positive radiologic response or stable disease revealed superior VEGFR-specific CTL reactivity and lower level of serum VEGF compared to samples from other patients with progressing malignant glioma. Plasma IL-8 level was negatively correlated with overall survival. These data indicate that these parameters may be potential immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines.

  • Immunotherapy targeting brain tumor stem cell antigen and niche

    2012.04
    -
    2015.03

    Keio University, TODA Masahiro, UEDA Ryo, Grant-in-Aid for Challenging Exploratory Research

     View Summary

    In this study, we demonstrated that glioma cells and brain tumor stem cells (BTSCs) expressed highly VEGF (vascular endothelial growth factor) and VEGFR (vascular endothelial growth factor receptor) in vitro. Furthermore, VEGFR was shown to express highly within malignant glioma tissues compared with surrounding brain tissue. In a clinical study, we performed a novel immunotherapy using VEGFR1/VEGFR2 peptides in 8 patients with recurrent malignant glioma and analyzed the cytotoxic T lymphocytes (CTLs) specific to VEGFR1/VEGFR2. After the vaccination with VEGFR1/VEGFR2, CTLs specific to VEGFR1 were induced in 6 out of 6 patients analyzed and CTLs specific to VEGFR2 in 2 out of 6 patients. These results suggest that an immunotherapy using VEGFR1/2 peptides to inhibit the VEGF/VEGFR signal may be effective for the treatment of malignant glioma.

  • Immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines against malignant glioma patients

    2012.04
    -
    2015.03

    Keio University, UEDA RYO, TODA Masahiro, Grant-in-Aid for Scientific Research (C)

     View Summary

    Immune-biomarkers and -assays are important for development of cancer immunotherapy to monitor immune induction following immunotherapy, and to evaluate anti-tumor effects early after immunotherapy. We characterized status of immune cells, cytokines, chemokines and other immunosuppressive molecules in recurrent malignant glioma patients who received vaccinations of VEGF receptor peptides. Peripheral blood samples from patients who demonstrated positive radiologic response or stable disease revealed superior VEGFR-specific CTL reactivity and lower level of serum VEGF compared to samples from other patients with progressing malignant glioma. These data indicate that these parameters may be potential immune-biomarkers for evaluation of clinical activity of VEGFR-targeted vaccines.

  • Analysis of stemness regulators in brain cancer stem cells

    2010
    -
    2012

    Keio University, TODA Masahiro, UEDA Ryo, Grant-in-Aid for Scientific Research (B)

     View Summary

    To identify genes that are highly expressed in brain cancer stem cells (BCSC), we performed cDNA microarray analysis using isolated BCSCs, glioma cells and neural stem cells, and identified a new BCSC antigen, KLRC2. To identify genes that regulate the st

display all >>

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, NEUROSURGERY

    2021